Salarius Pharmaceuticals, Inc. (SLRX)
Automate Your Wheel Strategy on SLRX
With Tiblio's Option Bot, you can configure your own wheel strategy including SLRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SLRX
- Rev/Share 0.0311
- Book/Share -5.8336
- PB -0.168
- Debt/Equity 0.0
- CurrentRatio 0.9174
- ROIC 57.9976
- MktCap 499450.0
- FreeCF/Share -29.1298
- PFCF -0.1205
- PE -0.0273
- Debt/Assets 0.0
- DivYield 0
- ROE -5.5647
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
Published: November 11, 2025 by: PRNewsWire
Sentiment: Neutral
HOUSTON , Nov. 11, 2025 /PRNewswire/ -- Salarius Pharmaceuticals, Inc. ("Salarius" or the "Company") (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting discounts and commissions and other offering expenses. The offering is comprised of 2,514,335 shares of its common stock ("Common Stock") and pre-funded warrants to purchase 2,152,331 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to an aggregate of 4,666,666 shares of Common Stock and Series B Warrants to purchase up to an aggregate of 4,666,666 shares of Common …
Read More
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025.
Read More
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer
Read More
About Salarius Pharmaceuticals, Inc. (SLRX)
- IPO Date 2015-01-29
- Website https://www.salariuspharma.com
- Industry Biotechnology
- CEO David J. Arthur
- Employees 2